Join to View Full Profile
950 Ryland StReno, NV 89502
Phone+1 775-329-0286
Fax+1 775-329-4243
Dr. Khanani is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Texas Tech University Health Sciences Center at LubbockResidency, Ophthalmology, 2005 - 2008
Baylor College of MedicineInternship, Internal Medicine, 2004 - 2005- Texas Tech University Health Sciences Center School of MedicineClass of 2004
Certifications & Licensure
NV State Medical License 2010 - 2025
TX State Medical License 2007 - 2012
American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
- Ocriplasmin Research to Better Inform Treatment (ORBIT) Start of enrollment: 2014 May 01
- A Retrospective Chart Review of Patients Treated With Ocriplasmin for Symptomatic VMA Start of enrollment: 2014 Aug 01
- Cooling Anesthesia for Intravitreal Injection Start of enrollment: 2018 Nov 30
- Join now to see all
Publications & Presentations
PubMed
- Bilateral paracentral acute middle maculopathy associated with open mitral valve repair.Humza Sulahria, Ohidul Mojumder, Greggory M Gahn, Arshad M Khanani
American Journal of Ophthalmology Case Reports. 2025-06-01 - Reply to Comment on: Subretinal Gene Therapy for Treatment of Retinal and Choroidal Vascular Diseases.Arshad M Khanani, Aamir A Aziz, Zoha A Khanani, Hannah Khan, Ohidul Mojumder
American Journal of Ophthalmology. 2025-04-01 - Faricimab Treat-and-Extend Dosing for Macular Edema due to Retinal Vein Occlusion: 72-Week Results From the BALATON and COMINO Trials.Carl J Danzig, Christiana Dinah, Faruque Ghanchi, Lars-Olof Hattenbach, Arshad M Khanani
Ophthalmology. Retina. 2025-03-17
Journal Articles
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationArshad M Khanani, Sunil S Patel, Philip J Ferrone, Pravin U Dugel, JAMA Ophthalmology
Authored Content
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
Press Mentions
Port System Cuts Injection Burden in Diabetic Eye DiseaseMarch 11th, 2025- Continuous Ranibizumab via Port Delivery System vs Monthly RanibizumabMarch 6th, 2025
- Extended Dosing Intervals Possible with Aflibercept in Diabetic Macular EdemaNovember 18th, 2024
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
